BMS’ Zeposia (ozanimod) Receives the US FDA’s Approval as New Oral Treatment for Relapsing Forms of Multiple Sclerosis

 BMS’ Zeposia (ozanimod) Receives the US FDA’s Approval as New Oral Treatment for Relapsing Forms of Multiple Sclerosis

BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma

Shots:

  • The approval is based on P-III SUNBEAM & RADIANCE Part B studies assessing Zeposia (0.92 mg, equivalent to 1mg) vs Avonex (interferon beta-1a, qw, IM) in 1,346 & 1,320 patients with RMS for at least 12 & 24mos. treatment period respectively
  • Collective results: @1yr. & @2yrs.; reduction in ARR of 48% & 38% (0.18 vs 0.35 & 0.17 vs 0.28); reduction in T1-weighted GdE brain lesions (0.16 vs 0.43 & 0.18 vs 0.37), reduction in number of new or enlarging T2 lesions (1.47 vs. 2.84 & 1.84 vs 3.18) respectively
  • Zeposia is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, act by blocking the capacity of lymphocytes to egress from lymph nodes thus reducing the number of lymphocytes in peripheral blood

Click here ­to­ read full press release/ article | Ref: BMS | Image: BMS

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post